金山科研平台，产品价格货期咨询微信：jinshanbio Source:E. coli-derived, Pro29-Met212 Accession #:Q75MH2 N-terminal Sequence Analysis:Pro29 Purity:>97%, by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin Level:< 0.01 EU per 1 μg of the protein by the LAL method. Predicted Molecular Mass:20.3 kDa Activity:Measured in a cell proliferation assay using T1165.85.2.1 mouse plasmacytoma cells. Nordan, R.P. etal. (1987) J. Immunol. 139:813.The ED₅₀ for this effect is typically 0.2 - 0.8 ng/mL. Formulation:Lyophilized from a 0.2 µm filtered solution in PBS and NaCl.See Certificate of Analysis for details. Molecule Information: IL-6 Long Name: Interleukin 6 Aliases: BSF-2; IFN-beta 2; MGI-2A Entrez Gene IDs: 3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 403985 (Canine); 493687 (Feline) Background: IL-6 View IL-6 IHC images.

Interleukin 6 (IL-6), also known as interferon-beta 2, 26 kDa protein and B cell stimulatory factor-2 (BSF-2), is a pleiotropic α-helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is essential for the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22 kDa - 28 kDa phosphorylated and variably glycosylated molecule. Mature human IL-6 is 183 amino acids (aa) in length and shares 41% aa sequence identity with mouse and rat IL-6. Alternate splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties.

IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization. gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM. Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R. Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes. Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor.